Shares of Actelis Networks Inc (NASDAQ:ASNS) rose sharply in pre-market trading after the company announced a new contract.The contract value equals approximately 5.45% of the company’s current market capitalization. The networking solutions provider from Fremont, California, announced on Wednesday that it had secured around $0.3 million in orders for software and services from a major telecommunications carrier in Southern Europe, which is part of a global telecom group.Actelis Networks shares jumped 40.8% ...

每经AI快讯，10月3日，港股宜明昂科-B(01541.HK)涨超6%，截至发稿，涨6.69%，报15.15港元，成交 额4567.05万港元。 ...

Core Viewpoint - The stock of Yiming Oncology-B (01541) has increased by over 6%, currently trading at 15.15 HKD with a transaction volume of 45.67 million HKD, following the announcement of new clinical trial applications for its drug IMM2510 [1] Group 1: Clinical Developments - Yiming Oncology has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510, aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] - The company has also recently submitted two additional Phase III registration clinical trials for different types of lung cancer [1] Group 2: Research and Development Pipeline - According to a recent report from Guoyuan International, the company's research pipeline is continuously expanding, enhancing its risk resistance capabilities [1] - The clinical efficacy data for the CD47CD20 dual antibody (IMM0306) is reported to be excellent, with potential to become a significant drug in the autoimmune field [1] - Yiming Oncology is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology and autoimmune diseases [1]

Core Viewpoint - Moderna is a global leader in mRNA technology, with its development journey marked by three key phases: foundational technology establishment, explosive growth driven by the COVID-19 pandemic, and a challenging diversification phase in the post-pandemic era [2][10]. Group 1: Development History - Moderna was founded in 2010 in Massachusetts, focusing on solving core challenges in mRNA technology [3]. - The name "Moderna" is derived from "Modified RNA," reflecting its technological core [4]. - Initially, the company operated in stealth mode with support from Flagship Pioneering, concentrating on fundamental scientific challenges in mRNA [6]. - A significant milestone was reached in 2013 with a $240 million upfront payment from AstraZeneca, validating its technology platform [7]. - In 2015, Moderna's first candidate vaccine, mRNA-1440, entered Phase I clinical trials, marking its transition to clinical validation [8]. - Moderna went public in 2018, achieving the largest IPO in global biotech history at that time, raising crucial capital for its ambitious R&D pipeline [9]. Group 2: COVID-19 Boom and Explosive Growth - The COVID-19 pandemic acted as a catalyst for Moderna's potential, leading to rapid development of the mRNA-1273 vaccine, which received emergency use authorization in 2020 [11]. - The success of the COVID-19 vaccine resulted in explosive revenue and profit growth, transforming Moderna from a cash-burning R&D company to a well-known commercial biopharmaceutical giant [12]. Group 3: Strategic Transformation and Diversification - As global COVID-19 cases stabilize and vaccine demand declines, Moderna entered a critical strategic transformation phase in 2023 [13]. - The company shifted its focus from reliance on a single COVID-19 product to building a diversified product portfolio [14]. - The R&D pipeline now spans other infectious disease vaccines (e.g., RSV, influenza), cancer immunotherapy (e.g., personalized cancer vaccines), and treatments for rare diseases [15]. - Moderna anticipates a net loss of approximately $800 million in 2025, reflecting a sharp decline in post-pandemic revenues [16]. Group 4: Core Investment Value - The core investment value of Moderna lies in its robust late-stage pipeline, particularly two major products: - Personalized cancer vaccine mRNA-4157, in collaboration with Merck, is undergoing Phase III trials for melanoma and non-small cell lung cancer, with data expected in 2026 [17]. - Seasonal influenza vaccine mRNA-1010 shows potential superiority over existing vaccines, with a projected market entry in 2025-2026 [18]. Group 5: Competitive Advantages and Technology Platform - Moderna's primary competitive advantage is its end-to-end mRNA technology platform, designed to guide human cells in producing specific proteins for disease prevention or treatment [19]. - The platform consists of three pillars: - Nucleotide modification technology enhances mRNA stability and translation efficiency [21]. - Lipid nanoparticle (LNP) delivery system ensures precise and efficient drug delivery [22]. - Scalable production processes allow rapid application across different products, aiming for long-term gross margins of 75%-80% [23]. Group 6: Product Pipeline and Market Potential - Moderna has over 40 projects in its pipeline, covering infectious diseases, cancer immunotherapy, rare diseases, and autoimmune diseases, creating a diversified product matrix [30]. - Key late-stage assets expected to contribute revenue in the coming years include CMV vaccine (mRNA-1647), influenza vaccine (mRNA-1010), and personalized cancer vaccine (mRNA-4157), targeting multi-billion dollar markets [31]. Group 7: Financial Data Analysis - Moderna's revenue is projected to plummet from $19.3 billion in 2022 to $1.93 billion in 2024, with a net loss of approximately $800 million expected in 2025 [43]. - The company has lowered its 2025 revenue guidance from $1.5-2.5 billion to $1.5-2.2 billion due to deferred contract revenues [44]. - To address revenue declines, Moderna has initiated a comprehensive cost control plan, including a 10% workforce reduction and a 25% cut in capital expenditure guidance for 2025 [45][46]. Group 8: mRNA Vaccine Market Landscape - The global mRNA drug market is experiencing strong growth, expanding from infectious disease vaccines to cancer immunotherapy and rare disease treatments [51]. - The market is currently dominated by a duopoly of Moderna and Pfizer/BioNTech, with Moderna holding approximately 24.2% market share and Pfizer/BioNTech at 19.8% [54]. - Both companies are diversifying their product pipelines, focusing on new areas such as influenza and RSV vaccines [55].

Core Viewpoint - CICC initiates coverage on Immune-Onc Biologics-B (09606) with an "outperform" rating, estimating a fair market value of HKD 37.9 billion and a target price of HKD 43.0, indicating a 20.1% upside from the current stock price [1] Industry Overview - Antibody-drug conjugates (ADCs) are among the most promising and rapidly developing drug forms globally, with the ADC market projected to grow from approximately USD 10.4 billion in 2023 to USD 115.1 billion by 2032 [1] - The next generation of ADCs is continuously exploring molecular design and target optimization, with potential applications expanding from oncology to autoimmune diseases [1] Company Highlights - Immune-Onc Biologics has established four distinctive ADC technology platforms and has secured licensing agreements with multinational pharmaceutical companies such as BioNTech, BeiGene, Avenzo, and GlaxoSmithKline, with a total transaction value exceeding USD 6 billion [2] - The company's global collaborative R&D is expected to enhance its innovative platform, driving a "flywheel effect" for ADC innovation [2] Pipeline and Development - The first ADC is anticipated to submit a market application in 2025, with DB-1303 (HER2 ADC) targeting endometrial cancer in the U.S. and breast cancer in China [3] - DB-1311 (B7-H3 ADC) shows potential as a best-in-class candidate in prostate cancer, while DB-1310 (HER3 ADC) is expected to follow closely; DB-1305 (TROP2 ADC) and dual-antibody combinations are leading in global exploration [3] Market Differentiation - The market tends to evaluate companies based on individual clinical pipeline valuations, while CICC emphasizes the investment value of Immune-Onc Biologics as a validated platform innovator in the ADC field, suggesting that a strong platform may incubate more valuable pipelines in the long term [4] - Potential catalysts include the U.S. and China market applications for DB-1303 and the initiation of clinical registration for DB-1311 [4]

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.MRNA has rallie ...

Core Viewpoint - Yiming Oncology-B (01541) saw a stock increase of over 7%, currently trading at 14.4 HKD with a transaction volume of 29.21 million HKD, following the announcement of clinical trial applications for its drug IMM2510 aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune therapy-resistant NSCLC [1] - Additionally, two Phase III registration clinical trials for different types of lung cancer have been submitted recently [1] Group 2: Research Data - Recent Phase I study data presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immune therapy, IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% (13/17) [1] - The median duration of response (DoR) was reported as 7.59 months (95% CI: 4.07 - NA), and the median progression-free survival (PFS) was 9.4 months (95% CI: 1.87 - NA) [1]

每经AI快讯，10月2日，港股三叶草生物-B(02197.HK)涨超21%，截至发稿，涨21.15%，报2.75港元， 成交额4221.86万港元。 ...

消息面上，今年6月，三叶草生物宣布，用于评估基于公司独有的 Trimer-Tag （蛋白质三聚体化）疫苗 研发平台开发的呼吸道联合疫苗候选产品SCB-1022（RSV+hMPV）与SCB-1033（RSV+hMPV+PIV3） （Pre-F 三聚体亚单位疫苗抗原）已完成首批受试者入组，正式启动 I 期临床试验。三叶草生物首席执 行官兼执行董事梁果此前指出，当前已批准上市的重组蛋白RSV疫苗虽然安全有效，但全球仍存在关键 未满足的临床需求——包括无法预防和减轻因人偏肺病毒（hMPV）和副流感病毒3型（PIV3）等由类 似 RSV 结构病毒造成的呼吸道疾病负担。 智通财经APP获悉，三叶草生物-B(02197)涨超21%，截至发稿，涨21.15%，报2.75港元，成交额4221.86 万港元。 ...

Core Viewpoint - The stock of Clover Biopharmaceuticals-B (02197) has surged over 21%, reaching HKD 2.75 with a trading volume of HKD 42.22 million, following the announcement of the initiation of Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 and SCB-1033 [1] Group 1 - Clover Biopharmaceuticals has completed the enrollment of the first batch of trial participants for its RSV+hMPV vaccine candidate SCB-1022 and the RSV+hMPV+PIV3 candidate SCB-1033, marking the official start of Phase I clinical trials [1] - The CEO of Clover Biopharmaceuticals, Liang Guo, highlighted that while currently approved recombinant protein RSV vaccines are safe and effective, there remains a significant unmet clinical need globally [1] - The unmet clinical needs include the inability to prevent and alleviate respiratory diseases caused by human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), which are structurally similar to RSV [1]